Editorial: Multi-organ linkage pathophysiology and therapy for NAFLD and NASH.
作者信息
Kimura Takefumi, Yamazaki Tomoo, Estrela Gabriel Rufino
机构信息
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto, Japan.
Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Japan.
出版信息
Front Endocrinol (Lausanne). 2024 Jun 5;15:1418066. doi: 10.3389/fendo.2024.1418066. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Multi-organ linkage pathophysiology and therapy for NAFLD and NASH.社论：非酒精性脂肪性肝病和非酒精性脂肪性肝炎的多器官联动病理生理学与治疗
Front Endocrinol (Lausanne). 2024 Jun 5;15:1418066. doi: 10.3389/fendo.2024.1418066. eCollection 2024.
2
Metabolic Muddle. MASLD and MASH on the Horizon.代谢混乱。MASLD 和 MASH 即将出现。
J Insur Med. 2023 Jul 1;50(2):147-149. doi: 10.17849/insm-50-2-147-149.1.
3
Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.经活检证实的脂肪性肝病和脂肪性肝炎患者的循环激素：一项多中心观察性研究。
Metabolism. 2023 Nov;148:155694. doi: 10.1016/j.metabol.2023.155694. Epub 2023 Sep 25.
4
Therapeutic management of metabolic dysfunction associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的治疗管理。
United European Gastroenterol J. 2024 Mar;12(2):177-186. doi: 10.1002/ueg2.12525. Epub 2024 Jan 9.
5
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.代谢相关脂肪性肝病：新命名对美国肝病研究学会非酒精性脂肪性肝病实践指南的影响及更新。
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
6
Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice.非酒精性脂肪性肝病（NAFLD）的筛查、诊断和分期：学会指南在临床实践中的应用。
Curr Gastroenterol Rep. 2023 Oct;25(10):213-224. doi: 10.1007/s11894-023-00883-8. Epub 2023 Sep 28.
7
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.基于肝活检的验证、确认和比较新型及传统非酒精性脂肪性肝病无创性诊断指标的诊断效能：一项多中心大样本研究。
Metabolism. 2023 Oct;147:155666. doi: 10.1016/j.metabol.2023.155666. Epub 2023 Jul 30.
8
Incretin-based investigational therapies for the treatment of MASLD/MASH.基于肠降血糖素的治疗 MASLD/MASH 的研究性疗法。
Diabetes Res Clin Pract. 2024 May;211:111675. doi: 10.1016/j.diabres.2024.111675. Epub 2024 Apr 16.
9
Patient-reported outcomes in patients with non-alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire-non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.非酒精性脂肪性肝病患者的患者报告结局：慢性肝病问卷-非酒精性脂肪性肝病/非酒精性脂肪性肝炎的叙述性综述
J Gastroenterol Hepatol. 2021 Mar;36(3):629-636. doi: 10.1111/jgh.15172. Epub 2020 Jul 16.
10
Histidine-rich glycoprotein in metabolic dysfunction-associated steatohepatitis-related disease progression and liver carcinogenesis.富含组氨酸糖蛋白在代谢功能障碍相关脂肪性肝炎相关疾病进展及肝癌发生中的作用
Front Immunol. 2024 Feb 26;15:1342404. doi: 10.3389/fimmu.2024.1342404. eCollection 2024.
本文引用的文献
1
Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病中肝脏和心血管事件风险的血糖控制目标
Hepatol Res. 2024 Aug;54(8):753-762. doi: 10.1111/hepr.14025. Epub 2024 Feb 24.
2
Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease.代谢功能障碍相关脂肪性肝病与非酒精性脂肪性肝病之间的一致性
Hepatol Res. 2024 Jun;54(6):600-605. doi: 10.1111/hepr.14011. Epub 2024 Jan 17.
3
Nonalcoholic fatty liver disease without overlapping metabolic-associated fatty liver disease and the risk of incident type 2 diabetes.非酒精性脂肪性肝病不合并代谢相关脂肪性肝病与2型糖尿病发病风险
Liver Int. 2023 Nov;43(11):2445-2454. doi: 10.1111/liv.15661. Epub 2023 Jun 30.
4
2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease.两步法PLT16-AST44方法：非酒精性脂肪性肝病患者的简化肝纤维化检测系统
Hepatol Res. 2022 Apr;52(4):352-363. doi: 10.1111/hepr.13745. Epub 2022 Feb 2.
5
Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease.G 蛋白偶联受体在肝星状细胞中的作用及非酒精性脂肪性肝病抗纤维化治疗的方法。
Front Endocrinol (Lausanne). 2021 Dec 6;12:773432. doi: 10.3389/fendo.2021.773432. eCollection 2021.
6
Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.磁共振弹性成像联合 Fibrosis-4 与 FibroScan-天门冬氨酸氨基转移酶在非酒精性脂肪性肝炎相关纤维化药物治疗候选者中的检测。
Hepatology. 2022 Mar;75(3):661-672. doi: 10.1002/hep.32145. Epub 2021 Dec 15.
7
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.转录组学鉴定出血小板反应蛋白-2 是 NASH 和肝纤维化的生物标志物。
Hepatology. 2021 Nov;74(5):2452-2466. doi: 10.1002/hep.31995. Epub 2021 Aug 21.
8
Association Between 10-Year Fracture Probability and Nonalcoholic Fatty Liver Disease With or Without Sarcopenia in Korean Men: A Nationwide Population-Based Cross-Sectional Study.韩国男性中，无论是否存在肌少症，10 年骨折概率与非酒精性脂肪肝之间的关联：一项全国性基于人群的横断面研究。
Front Endocrinol (Lausanne). 2021 Mar 31;12:599339. doi: 10.3389/fendo.2021.599339. eCollection 2021.
9
The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - A longitudinal cohort study.非酒精性脂肪性肝病的肝外癌症发病风险高于肥胖症——一项纵向队列研究。
J Hepatol. 2019 Dec;71(6):1229-1236. doi: 10.1016/j.jhep.2019.08.018. Epub 2019 Aug 27.
10
Association between non-alcoholic fatty liver disease and cancer incidence rate.非酒精性脂肪性肝病与癌症发病率之间的关联。
J Hepatol. 2017 Nov 2. doi: 10.1016/j.jhep.2017.09.012.
Zotero 插件